Description

Paxlovid CAS NO 2628280-40-8 is a co-packaged oral antiviral medication specifically designed for the treatment of mild-to-moderate COVID-19 in high-risk adult and pediatric patients. Its core value proposition lies in its proven efficacy in reducing the risk of hospitalization and death from the virus. This product is essential for pharmaceutical manufacturers, compounding facilities, and research institutions engaged in antiviral drug development and production.

Application

• Primary use in the formulation of the finished Paxlovid antiviral medication for COVID-19 treatment.
• Active Pharmaceutical Ingredient (API) for clinical trial materials in antiviral research.
• Reference standard for analytical method development and quality control in pharmaceutical laboratories.
• Key intermediate in advanced research on SARS-CoV-2 protease inhibitors and related antiviral mechanisms.
• Procurement by government and non-governmental organizations for public health preparedness and stockpiling.

Basic Information

Product Name	Paxlovid
CAS No.	2628280-40-8
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	Nirmatrelvir/Ritonavir Co-Package; PF-07321332/Ritonavir; SARS-CoV-2 Mpro Inhibitor Co-Pack; COVID-19 Antiviral Co-Packaged Treatment; Paxlovid Co-Packaged Tablets; Nirmatrelvir and Ritonavir Combination Pack; PF-07321332 and Ritonavir Combination
EINECS	Contact for details

Quality Control

Our Paxlovid products are manufactured and handled under strict quality systems designed for pharmaceutical actives and finished dosage forms. Each batch is supported by comprehensive documentation, including a detailed Certificate of Analysis (COA) verifying identity, purity, potency, and conformity to relevant specifications. We ensure compliance with current Good Manufacturing Practices (cGMP) and support our partners with the documentation required for their regulatory submissions.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in its original packaging until use to minimize exposure to atmospheric humidity.

Specification

Item	Specification
Description	Co-packaged medication (Nirmatrelvir tablets & Ritonavir tablets)
Identification (HPLC/IR)	Conforms to reference standards
Assay (Nirmatrelvir)	98.0% - 102.0%
Assay (Ritonavir)	98.0% - 102.0%
Related Substances (HPLC)	Meets acceptance criteria
Uniformity of Dosage Units	Conforms to Ph. Eur./USP
Dissolution	Conforms to Ph. Eur./USP
Water Content (KF)	< 5.0%
Microbial Limits	Conforms to Ph. Eur./USP

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.